Invenra Inc., a Madison startup that developed a drug discovery platform to identify human multi-specific antibodies for immuno-oncology, is one of the four startups to receive an investment from Wisconsin’s Venture Investors.

The funding comes from the venture capital investment group’s new $75 million fund dedicated to health startups, which will be managed from Madison, Ann Arbor, Michigan, and Milwaukee.

The investment amounts were not disclosed, but Venture Investors says it makes initial investments between $250,000 and $2.5 million and follow-on investments between $5 million and $8 million over a five- to-seven year period, when a company is primed for acquisition or launches an initial public offering.

The other three companies are:

  • ViaLase Inc., a Corona Del Mar, California-based developer of a rapid surgical treatment for primary open-angle glaucoma,
  • HistoSonics Inc., an Ann Arbor-based developer of a noninvasive, autonomous robotic platform that can destroy tissue at the sub-cellular level,
  • Eximis Surgical Inc., a Louisville, Kentucky-based company that developed a surgical platform that enables specimen removal in laparoscopic surgery.

The founders of Invenra, ViaLase and HistoSonics led other companies that were also funded by Venture Investors. Read the full story here.